Detailed examination of tumors [RNASeq, WES, immunohistochemistry (IHC)] from patients enrolled in the M12-356 trial revealed that mutations for tubulin genes were differentially expressed in responders vs non-responders, with TTLL2, TTLL4, TUBB2A, TUBB2B, TUBG1 and TUBGCP2 mutations (1-3 per tumor) overexpressed in non-responders (172). This evidence concerns the gene TUBB2A and neoplasm.